Literature DB >> 7823359

Femoropopliteal-crural graft patency is improved by an intensive surveillance program: a prospective randomized study.

A Lundell1, B Lindblad, D Bergqvist, F Hansen.   

Abstract

PURPOSE: The purpose of this study was to evaluate whether intensive surveillance compared with routine follow-up examinations improves femoropopliteal/crural graft patency.
METHODS: After operation the patients were randomized to intensive (n = 79) or routine surveillance (n = 77). The groups were matched with regard to sex, diabetes, indication for surgical procedure, surgical procedure, and graft material. Intensive surveillance was clinical examination, ankle/brachial index measurements, and duplex scans 1, 3, 6, 9, 12, 15, 18, 21, 24, and 36 months after operation. Routine surveillance was clinical examination and ankle/brachial index measurements without duplex scanning 1, 12, 24, and 36 months after operation. Grafts with a decrease in ankle/brachial index of more than 0.15 compared with the initial postoperative ankle/brachial index or a duplex scan showing a graft or anastomotic stenosis of more than 50% underwent angiography and if necessary, a revision or repeat procedure. Occluded grafts were reopened with thrombectomy or thrombolysis or were replaced with a new graft.
RESULTS: Assisted primary cumulative vein graft patency in the intensive group (n = 56) compared with that in the routine surveillance group (n = 50) after 3 years was 78% versus 53% (chi square analysis, 4.51; one degree of freedom; p < 0.05). Secondary patency was 82% versus 56% (chi square analysis, 5.62; one degree of freedom; p < 0.05). Assisted primary cumulative e-polytetrafluoroethylene and composite graft patency after 1 year in the intensive group (n = 23) compared with that of the routine surveillance group (n = 20) was 57% vs 50% (chi square analysis, 2.17; one degree of freedom; p > 0.1). Secondary patency was 67% vs 54% (chi square analysis, 1.85; one degree of freedom; p > 0.1). Revisions were made on 14 patent and 10 thrombosed grafts in the intensive group and on four patent and 15 thrombosed grafts in the routine surveillance group. All except eight were made during the first postoperative year.
CONCLUSIONS: Intensive surveillance identified failing vein grafts leading to a significantly higher cumulative assisted primary and secondary patency compared with cumulative assisted primary and secondary patency after routine follow-up examination. The patency of e-polytetrafluoroethylene and composite grafts was not influenced by intensive surveillance.

Entities:  

Mesh:

Year:  1995        PMID: 7823359     DOI: 10.1016/s0741-5214(95)70241-5

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  15 in total

Review 1.  Vein quality in infrainguinal revascularisation: assessment by angioscopy and histology.

Authors:  Y G Wilson
Journal:  Ann R Coll Surg Engl       Date:  1998-01       Impact factor: 1.891

2.  Vein graft surveillance: is the case proven?

Authors:  D K Beattie; R M Greenhalgh; A H Davies
Journal:  Ann R Coll Surg Engl       Date:  1997-01       Impact factor: 1.891

Review 3.  Clinical Assessment of Peripheral Arterial Disease in the Office: What Do the Guidelines Say?

Authors:  Srini Tummala; Derek Scherbel
Journal:  Semin Intervent Radiol       Date:  2019-02-05       Impact factor: 1.513

Review 4.  2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  Marie D Gerhard-Herman; Heather L Gornik; Coletta Barrett; Neal R Barshes; Matthew A Corriere; Douglas E Drachman; Lee A Fleisher; Francis Gerry R Fowkes; Naomi M Hamburg; Scott Kinlay; Robert Lookstein; Sanjay Misra; Leila Mureebe; Jeffrey W Olin; Rajan A G Patel; Judith G Regensteiner; Andres Schanzer; Mehdi H Shishehbor; Kerry J Stewart; Diane Treat-Jacobson; M Eileen Walsh
Journal:  Circulation       Date:  2016-11-13       Impact factor: 29.690

5.  Asia-Pacific Consensus Statement on the Management of Peripheral Artery Disease: A Report from the Asian Pacific Society of Atherosclerosis and Vascular Disease Asia-Pacific Peripheral Artery Disease Consensus Statement Project Committee.

Authors:  Maria Teresa B Abola; Jonathan Golledge; Tetsuro Miyata; Seung-Woon Rha; Bryan P Yan; Timothy C Dy; Marie Simonette V Ganzon; Pankaj Kumar Handa; Salim Harris; Jiang Zhisheng; Ramakrishna Pinjala; Peter Ashley Robless; Hiroyoshi Yokoi; Elaine B Alajar; April Ann Bermudez-Delos Santos; Elmer Jasper B Llanes; Gay Marjorie Obrado-Nabablit; Noemi S Pestaño; Felix Eduardo Punzalan; Bernadette Tumanan-Mendoza
Journal:  J Atheroscler Thromb       Date:  2020-07-04       Impact factor: 4.928

Review 6.  Transitions of care and long-term surveillance after vascular surgery.

Authors:  Andrew W Hoel; Kimberly C Zamor
Journal:  Semin Vasc Surg       Date:  2015-10-01       Impact factor: 1.000

Review 7.  Bypass surgery for lower extremity limb salvage: vein bypass.

Authors:  Hosam F El-Sayed
Journal:  Methodist Debakey Cardiovasc J       Date:  2012 Oct-Dec

8.  CKD accelerates development of neointimal hyperplasia in arteriovenous fistulas.

Authors:  Taku Kokubo; Noriyuki Ishikawa; Hisashi Uchida; Sara E Chasnoff; Xun Xie; Suresh Mathew; Keith A Hruska; Eric T Choi
Journal:  J Am Soc Nephrol       Date:  2009-05-07       Impact factor: 10.121

9.  The correlation between computed tomography and duplex evaluation of autogenous vein bypass grafts and their relationship to failure.

Authors:  Jonathan Rehfuss; Salvatore Scali; Yong He; Bradley Schmit; Kenneth Desart; Peter Nelson; Scott Berceli
Journal:  J Vasc Surg       Date:  2015-09-10       Impact factor: 4.268

10.  Endovascular therapy is effective treatment for focal stenoses in failing infrapopliteal vein grafts.

Authors:  Gregory G Westin; Ehrin J Armstrong; Usman Javed; Christopher R Balwanz; Haseeb Saeed; William C Pevec; John R Laird; David L Dawson
Journal:  Ann Vasc Surg       Date:  2014-08-06       Impact factor: 1.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.